| row-start col-md-7 #top-section top-section new-section |
Agenda
Please find below the content for each session. Note that all times are adjusted to GMT (UK time).
| Session 1 - NICE's review of HTA Methods 23/11/2021 15:00 - 17:30 (UK time) |
Timing | ||||||
| Welcome & introductions: opening remarks | 15 minutes | ||||||
| Discussion | 1h45 | ||||||
| Scope and experience of the process, including stakeholder engagement and participation in working groups Overview of the case for change and proposals Valuing the benefits of technologies and structured decision making Understanding and improving the evidence Challenging technologies: ATMPs, histology independent technologies |
|||||||
| Q&A | 25 minutes | ||||||
| Concluding remarks, presentation of next session and end of the workshop | 5 minutes | ||||||
|
Session 2 – Commercial and Managed Access Agreements at NICE This initiative will be part of the II Rebrats Congress and the XII Health Technology Assessment Network of Americas (RedETSA) Annual Meeting and requires a separate registration at this link |
Timing | ||||||
| Welcome & introductions | 5 minutes | ||||||
|
Discussion Evolution of managed access agreements: the innovative medicines fund Data collection and sources of evidence Case studies of data collection forms Managed access in England Patient Access schemes Standalone Commercial Access Agreements Commercial Access Arrangements as part of Managed Access History and current policy context Commercial access in England |
1h30 | ||||||
| Q&A | 20 minutes | ||||||
| Concluding remarks, presentation of next session and end of the workshop | 5 minutes | ||||||
| Session 3 – Clinical Guidelines and Implementation Support Tools at NICE 07/12/2021 15:00 - 17:30 (UK time) |
Timing | ||||||
| Welcome & introductions | 15 minutes | ||||||
| Discussion | 2h | ||||||
|
Use of GRADE for assessing quality of evidence Developing living guidelines - including facilitating strategies for the development of guidelines during COVID-19 Contextualisation of clinical guidelines ot other jurisdictions Topics prioritisation in clinical guidelines Stakeholders involvement in guideline development Understanding the levers for implementing guidelines and NICE’s role and tools for implementation - including impact measurement of the use of guidelines and the challenges and strategies for guideline implementation |
|||||||
| Q&A | 20 minutes | ||||||
| Concluding remarks and end of workshop series | 5 minutes | ||||||
